Gilead Sciences (Nasdaq:GILD) - Stock Price, News & Analysis

GILD Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 58.6% below our estimate of its fair value

Earnings are forecast to grow 7.8% per year

Earnings grew by 32.6% over the past year

Analysts in good agreement that stock price will rise by 21.4%

Risk Analysis

Unstable dividend track record

Has a high level of debt

Gilead Sciences, Inc. Competitors

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$88.1b

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$91.4b

Amgen

NasdaqGS:AMGN

US$145.2b

AbbVie

NYSE:ABBV

US$270.8b

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share Price	US$75.27
52 Week High	US$89.74
52 Week Low	US$61.45
Beta	0.39
1 Month Change	-2.30%
3 Month Change	-2.84%
1 Year Change	19.74%
3 Year Change	20.92%
5 Year Change	-2.51%
Change since IPO	11,794.53%

We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Aug 11

Recent updates

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.75

May 16

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

May 02

Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet

Apr 17

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Feb 21

Gilead Sciences (NASDAQ:GILD) Will Pay A Larger Dividend Than Last Year At $0.75

Feb 07

Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 41% Discount?

Dec 05

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 16

Gilead's Kite gains license to Refuge Biotechnologies platform for blood cancer treatments

Oct 20

Gilead's Quality And Growth Potential Are Underappreciated

Oct 14

Gilead Sciences: Becoming A Cure

Oct 03

A Dive Into Gilead Sciences' New HIV Medication

Sep 22

Gilead Sciences goes ex-dividend tomorrow

Sep 13

Gilead Sciences: Don't Miss The Transformation

Sep 01

Gilead Is Too Cheap To Ignore And Set To Soar

Aug 21

Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly

Aug 18

Shareholder Returns

	GILD	US Biotechs	US Market
7D	-0.5%	-0.5%	-1.5%
1Y	19.7%	10.8%	13.8%

Return vs Industry: GILD exceeded the US Biotechs industry which returned 10.8% over the past year.

Return vs Market: GILD exceeded the US Market which returned 13.8% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement	2.8%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.6%
10% most volatile stocks in US Market	14.3%
10% least volatile stocks in US Market	2.5%

Stable Share Price: GILD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	17,000	Dan O'Day	https://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market Cap	US$93.79b
Earnings (TTM)	US$5.48b
Revenue (TTM)	US$27.38b

17.1x

P/E Ratio

3.4x

P/S Ratio

Is GILD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GILD income statement (TTM)
Revenue	US$27.38b
Cost of Revenue	US$5.63b
Gross Profit	US$21.75b
Other Expenses	US$16.26b
Earnings	US$5.48b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	4.40
Gross Margin	79.42%
Net Profit Margin	20.03%
Debt/Equity Ratio	119.7%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

68%

Payout Ratio

GILD Stock Overview

Rewards

Risk Analysis

Gilead Sciences, Inc. Competitors

NasdaqGS:REGN

US$88.1b

NasdaqGS:VRTX

US$91.4b

NasdaqGS:AMGN

US$145.2b

NYSE:ABBV

US$270.8b

Price History & Performance

Recent News & Updates

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of US$0.75 per share at 4.0% yield

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Recent updates

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of US$0.75 per share at 4.0% yield

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

European Commission Approves Gilead’S Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial

Gilead Sciences, Inc. Presents New Biktarvy® Data at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announces Week 96 Results from the Pivotal MYR301 Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepatitis Delta

Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care At Asco 2023

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.75

Gilead Sciences, Inc. (NasdaqGS:GILD) acquired Xinthera, Inc.

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

First quarter 2023 earnings: EPS misses analyst expectations

Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet

Lead Independent Director exercised options to buy US$671k worth of stock.

Upcoming dividend of US$0.75 per share at 3.7% yield

Chairman & CEO exercised options and sold US$385k worth of stock

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences, Inc. Announces Updated Positive Results from Three Cohorts of the Phase 2 Trophy-U-01 Study of Trodelvy®

Gilead Sciences (NASDAQ:GILD) Will Pay A Larger Dividend Than Last Year At $0.75

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. Announces U.S. FDA Approves Trodelvy in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Consensus EPS estimates increase by 11%

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Gilead Sciences, Inc. to Report Q4, 2022 Results on Feb 02, 2023

Gilead Sciences, Inc. Announces European Medicines Agency Validates Marketing Authorization Application for Trodelvy(R) (Sacituzumab Govitecan-Hziy) for Pre-Treated Hr+/Her2- Metastatic Breast Cancer

Gilead Sciences, Inc.'s Sunlenca(R) (Lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

Chairman & CEO exercised options and sold US$136k worth of stock

Kite's Tecartus Car T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response

Gilead Sciences, Inc. Announces New Data From Post-Hoc Analysis from Phase 3 TROPiCS-02 Study

Upcoming dividend of US$0.73 per share

Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 41% Discount?

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Senior VP notifies of intention to sell stock

Senior VP exercised options and sold US$126k worth of stock

Senior VP exercised options and sold US$106k worth of stock

Gilead Sciences, Inc Announces U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients

Consensus EPS estimates increase by 17%

Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis At the Liver Meeting® 2022

Price target increased to US$77.77

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations